Noramco™
Alan Majewski is currently the President & Group CFO at Noramco™, responsible for overall P&L for Noramco and CFO duties for three other companies within the portfolio. Previously, Alan was the CFO at Noramco, Inc. and Executive Vice President at Nippon Steel & Sumitomo Metal Corp.'s Standard Steel subsidiary. Alan also served as CFO at Standard Steel Holdings, LLC. Prior to these roles, Alan gained experience as an Audit Manager at PricewaterhouseCoopers. Alan holds a Master of Liberal Arts degree from the University of Pennsylvania, an MBA from Penn State University, and a Bachelor of Science in Accounting from Grove City College.
Noramco™
Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry: – Focusing on high-purity controlled substances – Leveraging intellectual property to devise the most efficient routes to APIs – Providing analytical data, chemical and physical properties, stability studies and regulatory assistance – Formulation friendly particle size grades and extended technical packages – Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply – Supporting world-class supply security of controlled-substances, from schedule I to schedule III